Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Trovagene Inc (NASDAQ:TROV)

0.59
Delayed Data
As of 4:00pm ET
 -0.036 / -5.75%
Today’s Change
0.59
Today|||52-Week Range
3.30
-71.90%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$23.9M

Company Description

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. Trovagene's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 was developed to have high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase 1b/2 clinical trial in patients with AML underway. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.

Contact Information

TrovaGene, Inc.
11055 Flintkote Avenue
San Diego California 92121
P:(858) 952-7570
Investor Relations:

Employees

Shareholders

Mutual fund holders2.75%
Individual stakeholders14.85%
Other institutional11.09%

Top Executives

Bill WelchPresident, Chief Executive Officer & Director
Mark ErlanderChief Scientific Officer
Karsten SchmidtChief Technology Officer
Elizabeth AndersonVice President-Finance & Administration
Nick NelsonVice President-Strategy & Corporate Development